Anju Ghangurde

4 days ago | insights.citeline.com | Anju Ghangurde

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No Supply Disruption In USDr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025. Dr Reddy's readies for tariffs scenario (Shutterstock)

1 week ago | insights.citeline.com | Anju Ghangurde

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down. More surprise inspections at foreign sites on the way (Shutterstock)

1 week ago | insights.citeline.com | Anju Ghangurde

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open UpIndustry Group’s Head Shares Views In Audio InterviewAnil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision.

2 weeks ago | insights.citeline.com | Anju Ghangurde

Transient FY26 For Syngene But Momentum In China +1 ProjectsAs biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions at a newly acquired biologics site in the US to mature into commercial opportunities. Syngene reaps gains of China +1 rebalancing (Shutterstock)

3 weeks ago | insights.citeline.com | Anju Ghangurde

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical TensionsNovotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed. Novotech's Chief on trial solutions that can adapt to evolving trade environments. (Shutterstock)